Moderna Inc. (NASDAQ: MRNA), a U.S.-based biopharmaceutical company, has announced long-term efficacy data for its recently approved respiratory syncytial virus (RSV) vaccine, mResvia, showing a decline in effectiveness to approximately 50% after 18 months. This is notably lower than the efficacy rates of RSV vaccines from competitors GSK and Pfizer, leading to a decline of around 11% in Moderna’s stock during trading.
The long-term data indicated that after 18 months, Moderna’s RSV vaccine, mResvia, demonstrated an efficacy rate of 49.9% to 50.3% against multiple symptoms of lower respiratory tract disease. In comparison, GSK has published efficacy data showing its Arexvy vaccine at 78.6% after two years, while Pfizer reported that its Abrysvo vaccine maintained 77.8% efficacy through the second half of its first season on the market.
Moderna’s mResvia is formulated with an mRNA sequence encoding a stabilized prefusion F glycoprotein, delivered using lipid nanoparticles, similar to the delivery method employed in Moderna’s COVID-19 vaccines. The vaccine received its first approval in the U.S. in May of this year, intended to protect adults aged 60 and older from lower respiratory tract disease caused by RSV infection.- Flcube.com
